Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

(2015) Russell T Burke et al.   Oncotarget

Phosphoinositide 3-kinase inhibitors in lymphoma

(2014) Emily Curran et al.   CURRENT OPINION IN ONCOLOGY

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia

(2014) Alessandro Gozzetti et al.   LEUKEMIA RESEARCH

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

(2013) Michael Hallek   AMERICAN JOURNAL OF HEMATOLOGY

How I treat patients with relapsed chronic lymphocytic leukaemia

(2013) Kirsty Cuthill et al.   BRITISH JOURNAL OF HAEMATOLOGY

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets

(2013) Meike Vogler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

(2013) Tait Shanafelt et al.   CANCER

Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future

(2013) Alexey V. Danilov   CLINICAL THERAPEUTICS

The changing paradigm of chronic lymphocytic leukemia management

(2013) Chiara Lobetti-Bodoni et al.   European Journal of Internal Medicine

BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies

(2013) Tadeusz Robak et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Novel agents for chronic lymphocytic leukemia

(2013) Mei Wu et al.   Journal of Hematology & Oncology

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

(2013) S E M Herman et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders

(2013) Seng-Lai Tan et al.   PHARMACOLOGY & THERAPEUTICS

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

(2013) Jan A. Burger   Current Hematologic Malignancy Reports

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

(2011) A Smith et al.   BRITISH JOURNAL OF CANCER

Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials

(2011)   HAEMATOLOGICA

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Chronic lymphocytic leukemia: planning for an aging population

(2010) John G Gribben   Expert Review of Anticancer Therapy

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

How I treat CLL up front

(2009) J. G. Gribben   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Treatment of elderly patients with chronic lymphocytic leukemia

(2009) Barbara Eichhorst et al.   LEUKEMIA & LYMPHOMA

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

(2008) Paul Thurmes et al.   LEUKEMIA & LYMPHOMA